Literature DB >> 28331651

Frequency of Early-Stage Lymphedema and Risk Factors in Postoperative Patients with Breast Cancer.

Aykut Soyder1, Engin Taştaban2, Serdar Özbaş3, Şükrü Boylu1, Hedef Özgün1.   

Abstract

OBJECTIVE: Lymphedema is a chronic major complication that is seen frequently post-operatively and has negative effects on quality of life. In our study, determining the early-stage postoperative lymphedema frequency and specifying the risk factors in its development has been aimed.
MATERIALS AND METHODS: One hundred one cases that were operated on for breast cancer were evaluated regarding the 12-month control of their clinical specifications, histopathological specifications, and specifications related with the surgical intervention retrospectively. The data related to the parameters envisioned as risk factors were evaluated.
RESULTS: Lymphedema development was found in 7 (6.9%) out of 101 cases constituting the study group. No significant difference (p>0.05) in terms of lymphedema development was determined among age, body mass index (BMI), chemotherapy (CT), postoperative seroma or infection, mastectomy with the dominant arm, and breast-conserving surgery (BCS), which were evaluated as risk factors. There was a significance (p<0.05) between the other risk factors, which were axillary dissection (AD), number of positive lymph nodes (LN), radiotherapy (RT), the tumor size (T), and lymphedema existence. In every case in which lymphedema was determined, it was seen that there was axillary LN involvement and 15≤LN were ablated in the dissection (p<0.05).
CONCLUSION: It is seen that AD, RT applied to the breast cancer patients, and T are important risk factors in early-stage lymphedema development. No early-stage lymphedema development was determined in any of the patients to whom sentinel lymph node dissection (SLND) was applied.

Entities:  

Keywords:  Lymphedema; breast cancer; incidence; risk factors

Year:  2014        PMID: 28331651      PMCID: PMC5351476          DOI: 10.5152/tjbh.2014.1973

Source DB:  PubMed          Journal:  J Breast Health        ISSN: 1306-0945


  37 in total

Review 1.  Incidence of breast carcinoma-related lymphedema.

Authors:  J A Petrek; M C Heelan
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

Review 2.  Arm edema in breast cancer patients.

Authors:  V S Erickson; M L Pearson; P A Ganz; J Adams; K L Kahn
Journal:  J Natl Cancer Inst       Date:  2001-01-17       Impact factor: 13.506

3.  Prognostic factors for lymphedema after primary treatment of breast carcinoma.

Authors:  A Herd-Smith; A Russo; M G Muraca; M R Del Turco; G Cardona
Journal:  Cancer       Date:  2001-10-01       Impact factor: 6.860

4.  Breast cancer-related lymphedema--what are the significant predictors and how they affect the severity of lymphedema?

Authors:  Atilla Soran; Gina D'Angelo; Mirsada Begovic; Figen Ardic; Ali Harlak; H Samuel Wieand; Victor G Vogel; Ronald R Johnson
Journal:  Breast J       Date:  2006 Nov-Dec       Impact factor: 2.431

5.  An audit of the incidence of arm lymphoedema after prophylactic level I/II axillary dissection without division of the pectoralis minor muscle.

Authors:  G Querci della Rovere; I Ahmad; P Singh; S Ashley; I R Daniels; P Mortimer
Journal:  Ann R Coll Surg Engl       Date:  2003-05       Impact factor: 1.891

6.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Authors:  Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

7.  Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer.

Authors:  D Kay Blanchard; John H Donohue; Carol Reynolds; Clive S Grant
Journal:  Arch Surg       Date:  2003-05

8.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

9.  Lymphedema after treatment of breast cancer.

Authors:  Cihangir Ozaslan; Bekir Kuru
Journal:  Am J Surg       Date:  2004-01       Impact factor: 2.565

10.  Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function.

Authors:  Sandra C Hayes; Monika Janda; Bruce Cornish; Diana Battistutta; Beth Newman
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

View more
  5 in total

Review 1.  The Adventure of Axillary Treatment in Early Stage Breast Cancer.

Authors:  Bekir Kuru
Journal:  Eur J Breast Health       Date:  2020-01-01

2.  Discussion of relationships among changes of pathological indicators, postoperative lymphedema of the upper limb, and prognosis of patients with breast cancer.

Authors:  Xiping Zhang; Binbin Tang; Dehong Zou; Hongjian Yang; Enqi Qiao; Xiangming He; Feijiang Yu
Journal:  Biosci Rep       Date:  2019-04-16       Impact factor: 3.840

3.  Validity and reliability of the Turkish version of the lymphedema symptom intensity and distress survey.

Authors:  Zeynep Deveci; Özgül Karayurt; Buket Çelik; Sibel Eyigör
Journal:  Turk J Phys Med Rehabil       Date:  2021-12-01

4.  Self-care practices, patient education in women with breast cancer-related lymphedema.

Authors:  Zeynep Deveci; Özgül Karayurt; Sibel Eyigör
Journal:  Turk J Phys Med Rehabil       Date:  2021-05-25

Review 5.  Lymphoedema After Breast Cancer Treatment is Associated With Higher Body Mass Index: A Systematic Review and Meta-Analysis.

Authors:  Astère Manirakiza; Laurent Irakoze; Lin Shui; Sébastien Manirakiza; Louis Ngendahayo
Journal:  East Afr Health Res J       Date:  2019-11-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.